Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M

May 13, 2025 10:47am

SGMO is trading at $0.449 down -$0.2967 or -39.7%

Cantor is acting as sole book-running manager for the offering.

SGMO announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock.

The combined offering price of each share of common stock and accompanying warrant is $0.50.
The combined offering price of each pre-funded warrant and accompanying warrant is $0.49.
The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold.
The accompanying warrant has an exercise price of $0.75 per share, will become exercisable 6 months from the date of issuance and will expire six years from the date of issuance.

The Bottom Line: UGLY, desperate is an act of suffering and extreme need fostered by anxiety. There better be a back-end to all those warrants?

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 3 min ago
RegMed Investors (RMi) Financing: Sangamo Therapeutics (SGMO) prices 12,235 M share offering at $0.50 to raise $23 M

6 hours 23 min ago
RegMed Investors’ (RMi) pre-open: Gravity

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.